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Abstract— Paediatric endocrinology is a medical specialty 
dealing with variations of physical growth and sexual development 
in childhood. Genetic anomalies that can cause disorders of sexual 
development in children are rare. Given this, sharing and 
collaboration on the small number of cases that occur is needed by 
clinical experts in the field.  The EU-funded EuroDSD project 
(www.eurodsd.eu) is one such collaboration involving clinical 
centres and clinical and genetic experts across Europe. Through 
the establishment of a virtual research environment (VRE) 
supporting sharing of data and a variety of clinical and 
bioinformatics analysis tools, EuroDSD aims to provide a research 
infrastructure for research into disorders of sex development. 
Security, ethics and information governance are at the heart of this 
infrastructure. This paper describes the infrastructure that is 
being built and the inherent challenges in security, availability and 
dependability that must be overcome for the enterprise to succeed. 
 
Index Terms— Data-Grids, Data security, Virtual Research 
Environment, Paediatric Endocrinology. 
 
I. INTRODUCTION 
ISORDERS of sex development (DSD) are a set of rare to 
very rare disorders affecting the genito-urinary tract and, 
in a lot of instances, the endocrine-reproductive system. 
Children born with DSD may be born with ambiguous genitalia 
and the resulting decision-making process of sex assignment 
can be extremely disturbing and difficult for parents, families 
and health-care professionals [1]. 
Given the rarity of the condition, there is an associated 
scarcity of data on DSD. In countries the size of Scotland for 
example, a dozen or so cases occur per year. To help improve 
the understanding and provision of therapy and potential 
treatments or interventions associated with DSD, there is a great  
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need to increase knowledge of the genetic and biochemical 
profiles which characterize DSD. Different genetic anomalies 
can cause different manifestations of DSD and associated other 
clinical complications. At the heart of much research in this area 
is the androgen receptor which is involved in controlling gene 
expression for genes associated with DSD and in determining 
the sex phenotype. In particular much DSD research is focused 
around androgen receptor co-factors that modulate sex steroid 
action [2]. 
Current European research on DSD is fragmented with 
vertical and cross-national integration of different but 
complementary disciplines. The EU FP7 EuroDSD project 
(www.eurodsd.eu) aims to establish a level of coherence that 
has so far been non-existent in this field. In so doing, EuroDSD 
aims to facilitate the study of multiple, complementary DSD 
research areas in order to make a significant step forward in the 
understanding of DSD. The intention is to bridge the gap 
between a variety of disciplines including clinical medicine, 
biochemistry, molecular genetics and molecular biology, 
through cross-national integration of resources and expertise 
across six European countries including the UK, France, 
Netherlands, Germany, Italy and Sweden. 
In order to achieve this level of integration, the central 
component of the project is the development of a Virtual 
Research Environment (VRE), designed to facilitate secure, 
flexible collaboration using state of the art technologies. This 
technical work is led by the National e-Science Centre (NeSC – 
www.nesc.ac.uk) in Glasgow and is the basis for this paper. 
This paper describes the challenges in implementing the 
VRE for the EuroDSD project. Section 2 goes into greater detail 
on the background clinical context. Section 3 reviews the 
concept of VRE. Section 4 discusses some important issues 
encountered during the requirements caption and system design. 
Section 5 discusses the detailed infrastructure requirements of 
the VRE in computational terms. Section 6 describes the 
implementation progress and results to date and section 7 draws 
conclusions and identifies areas of future work.  
II. PAEDIATRIC ENDOCRINOLOGY  
The clinical motivation for EuroDSD is to improve the 
understanding and therefore the provision of therapy for 
individuals with DSD. To that end, the project has identified 
three key areas of research that stand to benefit greatly from the 
use of collaborative informatics tools such as the VRE. These 
Towards a Virtual Research Environment for 
Paediatric Endocrinology across Europe 
Jipu Jiang, Richard Sinnott, Anthony Stell, John Watt, and Faisal Ahmed 
D
9th IEEE/ACM International Symposium on Cluster Computing and the Grid
978-0-7695-3622-4/09 $25.00 © 2009 IEEE
DOI 10.1109/CCGRID.2009.68
496
Authorized licensed use limited to: UNIVERSITY OF GLASGOW. Downloaded on November 4, 2009 at 04:39 from IEEE Xplore.  Restrictions apply. 
are analyses of the genetic profiles involved in DSD; the 
associated biochemical processes involved, and the process of 
androgen action to control gene expression.  
The overall project structure has been divided into six 
work-packages (WPs). WP1 involves the development of the 
VRE and WP6 focuses upon the development of a training 
portal for general clinical training and education on DSD. The 
following research areas make up the other four packages. 
A. Defining the Genetic Basis of DSD 
Work package WP2 aims to define and understand the 
genetic basis of DSD. Using state of the art re-sequencing 
technology, a comprehensive nucleotide sequence of the genes 
known to be involved in genitourinary tract development will be 
screened. Building on work that suggests that patients with 
gonadal anomalies are due to changes in gene copy number or 
gene microdeletion/duplication [3]-[8], the opportunity to better 
understand the genetic pathways involved in human gonadal 
development now exists. At the time of writing, a core set of 
genes have been identified which will form the basis for targeted 
gene-chips for screening of DSD and therefore provide new 
diagnostic possibilities. 
B. Enhancing Knowledge of Mediators of Androgen Action 
Work packages WP3 and WP4 are designed to study the 
functional consequences of DSD. A key process in this regard 
affected by DSD is the dependence of the sex phenotype on 
androgen action via the androgen receptor acting as gene 
expression control factor. WP3 aims to characterize the 
relevance of androgen receptor co-factors, which are relevant to 
normal pubertal development. WP4 aims to identify 
sex-specific methylation patterns, where the inhibition of 
specific bases at the DNA level can become genetic traits 
mediated by the androgen receptor. These studies will give 
highly valuable information in understanding the natural course 
of DSD. 
C. Defining the Biochemical Basis of DSD  
 Work package WP5 aims to evaluate steroid profiles in 
plasma and urine using gas chromatography and mass 
spectrometry technologies. The results of this work package 
will be utilized to define steroid metabolome fingerprints, which 
can then be linked to distinct disorders caused by mutations in 
steroidogenic enzymes or their co-factors [9]-[11]. WP5 is 
ultimately aiming at the analysis of the complete steroid 
metabolome in DSD patients with hitherto unknown causes of 
disease to discover novel steroidogenic disorders. This will also 
create new diagnostic algorithms and allow development of 
better diagnostic strategies in conjunction with genetic 
discovery approaches in EuroDSD.  
These key areas of research cross several disciplines, and the 
progress of the independent packages are mutually dependent 
and complementary to one another. The synergies through these 
work packages and overarching goals of EuroDSD are 
facilitated through the development, use and adoption of a 
targeted VRE for DSD research. 
III. VIRTUAL RESEARCH ENVIRONMENT  
A Virtual Research Environment (VRE) can be regarded as a 
common gateway, designed to help researchers in all disciplines 
manage the increasingly complex range of tasks involved in 
carrying out their research. Ideally a VRE should provide an 
extensible and personalisable framework that integrates various 
applications, services, and resources to support particular areas 
of research as a Problem-Solving Environment (PSE) [12]. The 
major benefit of a VRE is to support collaborative activities. 
That is, through a VRE, researchers from different domains, 
from different locations and with different but complementary 
research interests should be able to work cooperatively 
exploiting targeted tools for sharing data, for knowledge sharing 
and exploiting common application infrastructures.  
VREs are often used to provide the user front end to 
e-Infrastructures, e.g. those based upon Grid technology. A 
common requirement for e-Infrastructures is to provide 
seamless single sign-on and access to distributed heterogeneous 
resources. Many large-scale e-Infrastructures provide common 
security access models for example through X509-based public 
key infrastructures. Advances to support finer-grained access 
control and authorisation are needed in domains such as DSD. 
To support this, local sites offering resources (including data) 
need to be able to define and enforce their own access policies 
reflecting local ethics and consent of patients. These should be 
seamless enforced when accessing and using these resources 
through the VRE. 
IV. DESIGN ASSUMPTIONS 
It is intended that the EuroDSD VRE will support clinical, 
genetic and biochemical data access and integration from six 
European clinical centres providing care for patients with DSD 
as well as supporting an extensive portfolio of targeted 
services/tools to support all aspects of DSD research. The VRE 
will provide capabilities to link clinical data resources on a 
case-by-case basis as well as providing a variety of 
DSD-targeted bioinformatics applications/services to support 
the scientific research.  
Due to the heterogeneous nature of the data and tools in use 
by the various countries across Europe, seamless management 
of distributed data with various format and security policies and 
fine-grained Grid security is needed. Ultimately it is intended 
that each of the six centres will make available approximately 
300 well-characterized patients with DSD as the basis for a 
continuing data assessment during the funding period, along 
with large amount of biomaterial resources.  
The cornerstone of the VRE model is site autonomy. Each 
clinical site is solely responsible for deciding what data sets it 
can share, with which partner sites and in what context. To 
support this, the design of the VRE is driven by security, 
incorporating both the needs of the clinical community and 
ethical oversight required on information governance. Where 
feasible it is intended that the VRE supports automatic 
extraction of clinical data across partner sites and their sharing 
across EuroDSD subject to security and ethical requirements.  
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The acquisition of existing clinical and other data sets into the 
VRE allows for rapid assessment of populations in the proposed 
research clusters. Availability and fault tolerance of the VRE 
and associated resources are essential features of the VRE and 
its supporting e-Infrastructure.  
V. VRE REQUIREMENTS  
Due to cultural, historical and social considerations 
associated with DSD, lack of information and in turn limited 
resultant collaborations are two of the biggest obstacles for rare 
disorder research and treatment. Many DSD disorders have not 
yet been adequately studied, e.g. their genetic-phenotypic 
relationship and the impact of genetic anomalies, due to limited 
numbers of recorded clinical cases. In creating a VRE, 
incorporating clinical and genetic data from 6 national centres 
across Europe, EuroDSD will have a variety of patients with 
DSD available. This will allow for much richer, targeted studies 
on a previously unprecedented scale to be supported. The ability 
to perform detailed interrogation through a VRE of recorded 
cases with associated clinical information will facilitate highly 
efficient and targeted use of novel genetic and biochemical 
strategies for the identification of novel disorders associated 
with DSD.  
Based on requirements from DSD researchers, the most 
important resource to be established in the VRE is a centralized 
registry for recording detailed clinical data sets associated with 
DSD. The registry provides various functionality including 
basic querying of DSD cases; uploading of DSD cases, and 
edit/delete of DSD cases.  Data validation and adherence to a 
common data model is crucial to DSD research. The existing 
EuroDSD requirements capture and system design exercise has 
taken the following issues into careful consideration.  
A. Data Integration  
To design a heterogeneous data infrastructure requires a 
common understanding of data that may exist in different data 
resources across partner sites. Data heterogeneity, software and 
data storage heterogeneity and language heterogeneity must all 
be addressed to tackle this problem. To address this, a core data 
model has been agreed between all contributors of EuroDSD.  
To support this, a scoping exercise was performed at the 
beginning of the project to assess the support requirements of 
individual partner sites. As a result, the consortium agreed to 
use the Scottish Genital Anomaly Network (SGAN - 
http://www.sgan.nhsscotland.com/) template as the core dataset 
of the registry. 
The initial phase of the project was focused on aligning the 
separate centre data formats into an initial core data model that 
captures the agreed common data sets associated with DSD. 
However, partner sites continue to suggest refinements and 
secondary information to be added for DSD research. With this 
in mind, the VRE registry has been developed to be flexible and 
scalable to include further information, often specific to 
individual centres, into the back-end registry data repository. 
This flexibility is particularly important for the biochemical and 
genetic information held by sites required for genetic, genomic, 
and steroid analysis. ?
Furthermore, whilst some centres have defined and use their 
own databases and IT systems for DSD, some sites have not yet 
moved to completely storing patient information electronically. 
Excel spreadsheets are one of the more commonly used data 
formats for local DSD information. This brings challenges for 
automatic data federation.  
Based on this, three entry methods are provided: manual, 
bulk upload, and automatic. Manual entry requires a research 
nurse or local clinician to enter patient DSD clinical patient data 
through the VRE registry interface. Strict data validation and 
enforcement of data entry to adhere to the common data model 
is supported. Bulk upload enables Excel spreadsheets 
comprising many DSD patients to be uploaded in built to the 
registry through the VRE. In this model, numerous cases are 
parsed and inserted into the registry. It is also the case that 
where feasible, customized automatic extraction of clinical data 
sets across partner sites will be built with appropriate ethics 
approval. This model has not yet been implemented however. 
B. Security 
Due to the highly sensitive nature of the information being 
shared in the EuroDSD project, the security measures to be put 
in place must be enforced with the utmost rigour. The 
challenges faced in providing access to the distributed DSD 
information include: authentication; authorization; auditing; 
privacy and identity protection; data ownership, consent and 
data encryption.  
 
Authentication 
The most common way of supporting VRE authentication is 
via usernames and passwords. However when accessing 
heterogeneous resources through the VRE, each resource will 
has its own authentication requirements, which can mean 
multiple usernames and password to remember – in the worst 
case, a username/password combination for each resource.  
The Internet2 Shibboleth framework [13] solves such 
problems by providing a Single Sign-On (SSO) mechanism to 
distributed resources within a federation. Instead of users 
having to register and login to each site they visit, Shibboleth 
provides the ability for users to authenticate to their local 
institution, (who are best placed to authenticate individuals). 
Based on this, resources that exist across the federation are then 
able to decide whether they accept such authentication 
assertions from given sites.  
Although Shibboleth provides an enhanced framework and 
has been rolled out across the UK academic environment, it 
currently lacks support across all EuroDSD partner centres. For 
none-Shibboleth enabled organizations, the National e-Science 
Centre at Glasgow has provided a virtual home for EuroDSD 
users as their home institution for the federation. 
 
Authorization 
Building upon federated authentication models, Shibboleth 
provides the foundation to support and integrate Role Based 
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Access Control (RBAC) authorization mechanisms. To achieve 
this, it is necessary to assign digitally signed attribute 
certificates to EuroDSD participants. These are subsequently 
passed through Shibboleth to the VRE (seamlessly from the end 
user perspectives), for use by VRE to decide which resources 
can be accessed, to what level and to which users. 
  
Audit tracking 
Given the importance of the EuroDSD data, accountability 
has been identified as a key requirement of the VRE. A 
community-wide policy on usage and behaviour has been 
agreed and any operations over the data need to be recorded for 
future auditing. If any suspicious or malicious activity is found, 
the user who performed such action will be banned from the 
VRE to protect future patient data being tampered with.  
Users are treated equally in the VRE with their Shibboleth Id 
used as the unique identifier for users. The access to and usage 
of the portal is also monitored using the Google Analytics 
software (www.google.com/analytics/).  
 
Privacy and identity protection 
The purpose of the registry is to help clinicians search for 
DSD cases within Europe and beyond. If a suitable patient is 
found in the registry, e.g. for a particular DSD study, the 
researcher or clinician can contact the owner of the record for 
further information. The DSD records themselves do not 
contain any patient identifying data themselves, but they do 
include information on who added the case to the registry. 
Indeed the information provided in the SGAN template has 
been carefully and deliberately screened to avoid the possibility 
for identifying individuals. Thus for example, the Date of Birth 
in the SGAN template has been registered as Year of Birth in the 
VRE to help minimize the chance of patient identification. The 
demographic component of the registry only covers information 
relating to the clinical centre and the clinician that has uploaded 
the case.  
However, local identifiers, which are essential to retrieve the 
patient’s record in the hospital, can potentially reveal the 
identity of the patient. Given this, the local identifier of every 
patient must be encrypted for everyone except the record owner 
in the VRE.  
Further follow up through the registry, e.g. for exchange of 
biomaterials on particular cases is, subject to ethical approval, 
currently achieved through direct contact with the consulting 
clinician. We note also that the clinical data registry itself 
includes detailed information on whether such biomaterials are 
available and whether they have been screened for particular 
genes. 
 
Data ownership and consent 
Each clinical site is solely responsible for deciding what data 
sets it can share, with which partner sites and in what context. 
This brings up the issue of ownership and consent of patients 
records. Records in the registry are owned by the person who 
uploads them. Only the owner can have the right to edit and 
delete the records. This gives the owner the right to decide what 
to share and with whom.  
The owner can also decide who can see the records and in 
what context. The level of clinical patient consent is crucial here. 
To share data on the registry, clinicians must obtain consent 
from the patient or next of kin. Different countries have 
different policies regarding consent. For example, in UK, unless 
the patient has specifically opted in to the EuroDSD study, the 
data can be shared within the country, i.e. the UK, but not 
throughout Europe. To overcome the policy differences, the 
consortium has agreed on four levels of consent: local, e.g. for a 
particular clinic only; national, e.g. for sharing in a given 
country only; consent for sharing across the EuroDSD 
collaborators, and consent for sharing across the international 
community incorporating wider non-EuroDSD partners. 
Therefore, the VRE must be able to store the consent status of 
each record and enforce the consent level when users search 
these records. For example, a case enter from UK with consent 
of national level can only be seen by centres and researchers 
registered in UK, e.g. London, Cambridge and Glasgow. Other 
European countries cannot see such record.  
 
Encryption 
A further challenge in security is to protect the various 
data-sets whilst in transit from centres to the registry from 
eavesdropping, interception and modification. This is achieved 
by securing the channels of input and data transit using SSL 
over HTTPS. This is achieved as part of the Shibboleth 
authentication mechanism. 
The data at rest in the VRE repository is also similarly 
protected using encryption of data before it is uploaded and 
downloaded. This is done in an application-layer module 
between the VRE portal and the back-end associated database. 
C. Usability 
To minimize the learning curve of the EuroDSD VRE, 
usability is extremely important for the clinical experts from 
multiple disciplinary backgrounds. The VRE must be easy to 
use and information must be clearly presented. This has been 
taken into consideration when designing the VRE for clinicians 
and scientists. A simple colorful theme has been used for better 
presentation. The JavaScript and AJAX [14] environments 
allow a tailored access and usage experience for users.  
User feedback has been especially valuable in improving 
usability of a VRE. The interface has undergone numerous 
usability tests of clinicians and scientists, and will continue to be 
refined over the coming years. 
VI. IMPLEMENTATION  
The EuroDSD VRE itself has been based upon a rapid 
prototyping approach – exploiting a body of projects in this area 
at NeSC in Glasgow. Early prototypes were made available to 
the programme members for assessment, and improvements to 
the prototypes were made based on those feedbacks. The logical 
EuroDSD architecture depicting the various partner sites is 
shown in Fig. 1, in which partners sites performing different 
functions in the project are presented with different colors.  
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Based on feedback on the initial prototype and on an 
increasing set of requirements captured for the EuroDSD 
project, it was decided that a more flexible feature-set would be 
necessary for the VRE. Upon investigation and testing over 
several technologies, the Apache Struts2 [15], Spring 
framework [16], and Hibernate [17] were chosen for the 
implementation of EuroDSD VRE.  
 
Fig. 1.  Logical infrastructure supported by the VRE 
 
To provide maximum flexibility, the VRE architecture is 
classified into four layers. From top to bottom, the first layer is 
the presentation layer that provides multiple ways to display 
information, e.g. HTML, JSP, AJAX, etc. Beneath this, the 
second layer is specially designed to control targeted 
workflows. The third layer provides services to process 
EuroDSD specific logic. And at the bottom, the fourth layer 
offers support for data persistence. 
Based on this architecture, chosen frameworks will be 
deployed into the layers according to the features they provided. 
As a widely adopted Model View Controller (MVC) [18] 
framework, Struts2 will act as the controller of the VRE and 
provide presentation of the data. It supports the first and second 
layers of VRE. And Spring framework, as one of the most 
respected Inversion of Control (IoC) [19] container, will be in 
charge of the third layer to provide a wide range of services for 
EuroDSD business logics. Finally the Hibernate, at the bottom 
layer, will provide powerful yet high-performance data 
persistence service to the VRE.  
This solution significantly improved the overall flexibility, 
testability, and maintainability of the VRE. It was also 
compatible with most existing frameworks and standards, 
including JSR-168 portlet. We recognise that this is extremely 
important for the future when integrated with existing Grid tools 
support genetic and biochemistry research and collaboration. In 
addition, more useful features offered through this architecture 
include better community support, support of multiple 
presentation layer standards, and Spring Security framework 
based on Aspect Oriented Programming (AOP) [20]. 
 
Availability 
Most of the VRE implementation in the first prototype was 
rewritten for the new architecture. Thanks to the testability 
framework offered through Struts and Spring, the system can 
easily be modulated and tested. Based on this, bugs can be 
significantly reduced and the system robustness is increased.  
Based on the four-layer architecture, business logic is 
properly stripped from the presentation and data. This provides 
better maintainability for future system administrators, who do 
not have to know the whole system to maintain component parts 
of it. Clearer separation of the business logic layer also provides 
flexibility in choosing service providers. Such flexibility is also 
useful in later integration with further resources and tools. 
Further features and improvements have been implemented 
to provide better availability of the system. For example, it is 
normally the case that changes of configuration will typically 
require the restart of the Web server. Doing this will temporarily 
stop the services. However, in the EuroDSD VRE, 
configuration is dynamic and can be loaded into the VRE 
through scripts and property files. Such implementation models 
significantly reduce the number of server restarts and provide 
consistently available services to the EuroDSD community. 
 
Security 
In terms of security, the Shibboleth system is fully integrated 
into the VRE. Everything inside VRE must run through the 
Shibboleth authentication process. Users not at institutions 
involved in a federation have been offered a virtual home at 
NeSC-Glasgow. Based on consortium security requirements, 
each user has been assigned with roles, which are used for 
fine-grained access control. Two key roles in particular have 
currently been identified: EuroDSD_contributor and 
EuroDSD_researcher. A user with the EuroDSD_contributor 
role has the privilege to upload, edit, and withdraw cases in the 
registry, whilst users assigned the EuroDSD_researcher role can 
only search patient data.  
As identified by the consortium, patient information 
registered in VRE must retain anonymous and untraceable to 
patients. Therefore, the services have been implemented to take 
the responsibility to provide anonymous records for 
none-owners. Consent level enforcement is also achieved at this 
layer too. Such implementation allows ensuring that no sensitive 
information will be passed out beyond the VRE.  
So far the VRE implementation has secured every operation 
in the VRE (search, upload, edit, delete) according to roles 
assigned to individuals. As noted, HTTPS is used to encrypt 
communications between user browsers and the VRE, and 
between the VRE to data sources. Thus end users are 
completely oblivious of the underlying security used to enforce 
access and use of clinical data made available in the VRE. 
 
Usability 
Usability is extremely important for non-IT experts to use the 
VRE. This has been done in two key ways. Firstly, the VRE 
hides as much complexity as possible and provides unified 
access to heterogeneous resources. Secondly, the Human 
Computer Interface (HCI) components of the VRE have been 
developed to be as straightforward and easy to use as possible.  
Bearing this in mind, the implementation provides a unified 
access interface with user driven upload and query fields 
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supported. Wherever possible, selection boxes are used instead 
of text fields to ensure unified data formats (aligned with the 
core data model) and avoiding data entry confusion. For DSD it 
is important fill in a variety of DSD information. JavaScript has 
been used in the user interface to provide data validation and 
automatic calculations when possible. For example, the 
External Masculinisation Score is calculated based on user 
selections of five clinical fields. Invalid data and actions are 
shown immediately when moving to next data entry fields or on 
request submission. Last but not the least, AJAX technology is 
used to provide coherent flow of information without the need 
for page refreshing to interrupt user experience.   
 
Progress 
The first production system has been deployed online to 
provide 24*7 availability to EuroDSD clinicians and research 
groups since 1st December 2008. Clinical cases from multiple 
sites have been recorded and are now being accessed in the 
registry. Currently, 53 patient data has been added to the 
registry from three centres across Europe, and this number keep 
growing. At the same time, further requirements will be 
gathered from consortium to identify necessary tools for data 
analysis and collaborations. These tools will be integrated 
seamlessly into the VRE on top of the patient data collected.  
VII. CONCLUSIONS  
The work on the EuroDSD project is still very much on going. 
At present the focus has been very much upon support of the 
registry but next steps are looking more at collaborative tools to 
be offered through the VRE. This includes wikis discuss 
particular cases in the registry for example. The bioinformatics 
tool support and management of genetic data sets supported for 
analysis of novel genes will also be supported in the next 
version of the VRE. In this regard, bioinformatics applications 
supporting for example sequence analysis through BLAST [21] 
are currently being deployed. These will make use of large-scale 
HPC facilities such as ScotGrid (www.scotgrid.ac.uk) and the 
UK e-Science National Grid Service (www.ngs.ac.uk) – subject 
to ethics considerations on data use on HPC facilities.   
ACKNOWLEDGMENT 
The research leading to these results has received funding 
from the European Community's Seventh Framework 
Programme (FP7/2007-2013) under grant agreement number 
201444. The authors would like to acknowledge the ESPE DSD 
consortium that has contributed to the development of the 
prototype registry. We would also like to acknowledge the other 
partners in the EuroDSD project: Prof. Olaf Hiort, Dr. Ken 
McElreavey, Prof. Ieuan Hughes, Prof. Wiebke Arlt, Prof. 
Stenvert Drop, Prof. Paul-Martin Holterhus, Dr. Ralf Werner, 
Dr. John Davies, Prof. Lendert Looijenga, Dr. Martine Cools, 
Prof. John Achermann, Prof. Silvio Bertollini, Prof. Olle Soder, 
Dr. Anna Nordenstrom, Prof. Peter Wieacker, Dr. Susanne 
Ledig, Prof. Yves Morel, Dr Ole Ammerpohl, and Dr Felix 
Riepe. 
REFERENCES 
[1] Hiort O, Holterhus PM, Thyen U. “The basis of gender assignment in 
disorders of somatosexual differentiation”. Horm Res 64 (Suppl.2), 2005, 
18-22.  
[2] Bebermeier JH, Brooks J, DePrimo S, Werner R, Deppe U, Demeter J, 
Hiort O, Holterhus PM. “Cellline and tissue specific signatures of 
androgen receptor coregulator transcription”. J Mol Med, 2006, 84: 
919-31. 
[3] Tar A, Solyom J, Gyorvari B, Ion A, Telvi L, Barbaux S, Souleyreau N, 
Vilain E, Fellous M, McElreavey K. “Testicular development in a 46,XX 
true hermaphrodite with a deletion of distal Xp sequences”, 1995, Hum. 
Genet. 96: 464-468. 
[4] Wieacker P, Missbach D, Jakubiczka S, Borgmann S, Albers N. “Sex 
reversal in a child with the karyotype 46,XY”, 1996, dup (1) 
(p22.3p32.3). Clin Genet. 49: 271-3. 
[5] Veitia RA, Nunes M, Quintana-Murci L, Rappaport R, Thibaud E, 
Jaubert F, Fellous M, McElreavey K, Goncalves J, Silva M, Rodrigues JC, 
Caspurro M, Boieiro F, Marques R, Lavinha J. “Swyer syndrome and 
46,XY partial gonadal dysgenesis associated with 9p deletions in the 
absence of monosomy-9p syndrome”, 1998, Am J Hum Genet. 63: 901-5. 
[6] Aleck KA, Argueso L, Stone J, Hackel JG, Erickson RP. “True 
hermaphroditism with partial duplication of chromosome 22 and without 
SRY”, 1998 Am J Med Genet. 85: 2-4. 
[7] Bardoni B, Zanaria E, Guioli S, Floridia G, Worley KC, Tonini G, 
Ferrante E, Chiumello G, McCabe ERB, Fraccaro M, Zuffardi O, 
Camerino G. “A dosage sensitive locus at chromosome Xp21 is involved 
in male to female sex reversal”, 1994, Nature Genet. 7: 497-501. 
[8] Ogata T, Muroya K, Sasagawa I, Kosho T, Wakui K, Sakazume S, Ito K, 
Matsuo N, Ohashi H, Nagai T. “Genetic evidence for a novel gene(s) 
involved in urogenital development on 10q26”, 2000, Kidney Int. 58: 
2281-90. 
[9] Arlt W, Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, Chalder 
SM, Borucka-Mankiewicz M, Hauffa BP, Malunowicz EM, Stewart PM, 
Shackleton CH. “Congenital adrenal hyperplasia caused by mutant P450 
oxidoreductase and human androgen synthesis: analytical study”, 1994, 
Lancet, 363: 2128-2135. 
[10] Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, 
Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, 
Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM. 
“Mutations in the genes encoding 11?-hydroxysteroid dehydrogenase 
type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone 
reductase deficiency”, 2003, Nature Genetics, 34: 434-439. 
[11] Shackleton C, Marcos J, Malunowicz EM, Szarras-Czapnik M, Jira P, 
Taylor NF, Murphy N, Crushell E, Gottschalk M, Hauffa B, Cragun DL, 
Hopkin RJ, Adachi M, Arlt W. “Biochemical diagnosis of Antley- Bixler 
syndrome by steroid analysis”, 2004, American Journal of Medical 
Genetics A, 128: 223-231. 
[12] E. Gallopoulos, E. Houstis, and J.R. Rice. Problem- 
Solving Environments for Computational Science. 
IEEE Computational Science and Engineering, 1:11–23, 1994. 
[13] The Internet2 Shibboleth framework http://shibboleth.internet2.edu 
[14] Jesse James Garrett (2005-02-18). Ajax: A New Approach to Web 
Applications. AdaptivePath.com. Retrieved on 2008-06-19. Available: 
http://www.adaptivepath.com/ideas/essays/archives/000385.php 
[15] Struts2 Framework. Available:  http://struts.apache.org/2.x/ 
[16] Spring Framework. Available:  http://www.springsource.org/ 
[17] Hibernate. Available:  http://www.hibernate.org/ 
[18] Trygve M. H. Reenskaug (1978). MVC. XEROX PARC 1978-79. 
Available: http://heim.ifi.uio.no/~trygver/themes/mvc/mvc-index.html 
[19] Martin Fowler (2004). Inversion of Control Containers and the 
Dependency Injection pattern. Available: 
http://martinfowler.com/articles/injection.html#InversionOfControl 
[20] Kiczales, Gregor; John Lamping, Anurag Mendhekar, Chris Maeda, 
Cristina Lopes, Jean-Marc Loingtier, and John Irwin. “Aspect-Oriented 
Programming”, 1997, Proceedings of the European Conference on 
Object-Oriented Programming vol.1241. pp. 220–242.   
[21] Sinnott,R.O. Stell,A.J. Bayer,M.M. Koetsier,J. “Grid Infrastructures for 
Secure Access to and Use of Bioinformatics Data: Experiences from the 
BRIDGES Project”. The First International Conference on Availability, 
Reliability and Security (ARES-2006), Vienna, Austria, April, 2006. 
501
Authorized licensed use limited to: UNIVERSITY OF GLASGOW. Downloaded on November 4, 2009 at 04:39 from IEEE Xplore.  Restrictions apply. 
